KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Total Debt: 2009-2025

Historic Total Debt for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $16.8 billion.

  • Teva Pharmaceutical Industries' Total Debt fell 11.54% to $16.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 billion, marking a year-over-year decrease of 11.22%. This contributed to the annual value of $17.8 billion for FY2024, which is 10.34% down from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' Total Debt stood at $16.8 billion, which was down 2.54% from $17.2 billion recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Total Debt peaked at $25.1 billion during Q2 2021, and registered a low of $16.7 billion during Q1 2025.
  • Moreover, its 3-year median value for Total Debt was $19.0 billion (2024), whereas its average is $18.8 billion.
  • Data for Teva Pharmaceutical Industries' Total Debt shows a maximum YoY declined of 15.24% (in 2025) over the last 5 years.
  • Over the past 5 years, Teva Pharmaceutical Industries' Total Debt (Quarterly) stood at $23.0 billion in 2021, then decreased by 7.95% to $21.2 billion in 2022, then decreased by 6.50% to $19.8 billion in 2023, then decreased by 10.34% to $17.8 billion in 2024, then declined by 11.54% to $16.8 billion in 2025.
  • Its last three reported values are $16.8 billion in Q3 2025, $17.2 billion for Q2 2025, and $16.7 billion during Q1 2025.